IJTMGH International Journal of Travel Medicine and Global Health

Int J Travel Med Glob Health. 2026 Jun;14(2):128-135 doi 10.30491/ijtmgh.2025.544662.1503
http://ijtmgh.com

Perspective Open Access

Targeting Ketone Burden in Diabetic Ketoacidosis: A Novel IV Infusion Linking Glycine Cleavage, Cofactor Optimization, and Antioxidant Defense

Maher Monir Akl [1]* , **Amr Ahmed** [2]

[1] Faculty of Medicine, National Research Lobachevsky State University of Nizhny Novgorod, 603022, Nizhny Novgorod, Russia.
[2] The public health department, Riyadh First Health Cluster, Ministry of Health, Saudi Arabia

***Corresponding Author:** Maher Monir Akl, Faculty of Medicine, National Research Lobachevsky State University of Nizhny Novgorod, 603022, Nizhny Novgorod, Russia. Email: maherakl555@gmail.com; s25450791@unn.ru, Phone: +79960433365

Received 2025-09-02; **Accepted** 2025-11-05; **Online Published** 2026-06-01

Abstract

Diabetic ketoacidosis (DKA) remains a critical emergency with mortality of 1–5% and an annual U.S. healthcare burden exceeding 2 billion USD. Standard management with insulin, fluids, potassium, and bicarbonate halts ketogenesis but does not actively accelerate ketone clearance, address oxidative stress, or restore depleted cofactors. These gaps prolong resolution (12–24 hours) and hospital stays (3–4 days). We propose the DKA-Rescue IV infusion, a formulation combining Ringer's lactate, sodium bicarbonate, potassium chloride, glycine, thiamine, and N-acetylcysteine (NAC). Glycine may enhance ketone conjugation via the mitochondrial glycine cleavage system, thiamine could support pyruvate dehydrogenase activity to limit lactate buildup, and NAC may replenish glutathione and mitigate oxidative stress. Modeling suggests faster correction of acidosis and ketone clearance, though this remains to be validated clinically. Feasibility is supported by low estimated production costs (8–15 USD/L) and osmolarity within the physiologic range. This framework represents a potential adjunct to current DKA care and warrants early-phase clinical trials to evaluate safety and efficacy.

Keywords: Diabetic ketoacidosis, intravenous infusion, glycine cleavage system, thiamine pyrophosphate, N-acetylcysteine, ketone metabolism, oxidative stress, metabolic acidosis, electrolyte imbalance, clinical recovery.

Citation: Akl MM, Ahmed A. Targeting Ketone Burden in Diabetic Ketoacidosis: A Novel IV Infusion Linking Glycine Cleavage, Cofactor Optimization, and Antioxidant Defense. Int J Travel Med Glob Health, 2026;14(2):128-135. Doi:10.30491/ijtmgh.2025.544662.1503.

Introduction

Diabetic ketoacidosis represents a severe metabolic complication primarily associated with type 1 diabetes, though increasingly observed in type 2 diabetes under conditions of insulin deficiency or resistance. This condition arises from profound insulin shortage, leading to unchecked lipolysis, elevated free fatty acid mobilization, and subsequent hepatic ketogenesis [1]. The accumulation of ketone bodies, including acetoacetate and β-hydroxybutyrate, induces metabolic acidosis, profound dehydration, and electrolyte disturbances, culminating in life-threatening systemic effects if untreated [2]. Annual incidence in the United States reaches approximately 220,340 hospital admissions, with mortality rates ranging from 1% to 5% in developed settings, influenced by factors such as delayed presentation and comorbid conditions [3].

Standard management protocols, as outlined in established guidelines, emphasize rapid insulin administration to suppress ketogenesis, intravenous fluid resuscitation to restore intravascular volume and correct dehydration, and targeted electrolyte replacement, particularly potassium, to mitigate hypokalemia risks during insulin therapy [4]. Bicarbonate supplementation is reserved for severe acidosis with pH below 6.9, aiming to stabilize cardiac and respiratory functions.

Despite these interventions, resolution typically requires 12 to 24 hours, during which persistent ketone elevation and acidosis perpetuate risks of cerebral edema,

acute kidney injury, and cardiovascular instability [5,6]. Key limitations include incomplete addressing of oxidative stress from reactive oxygen species generated by ketones, metabolic inefficiencies due to cofactor depletions, and delayed clearance of existing ketone bodies, as insulin primarily halts new production rather than accelerating breakdown of accumulated metabolites [7,8].

The proposed DKA-Rescue IV infusion introduces an innovative formulation that synergistically combines conventional elements with targeted metabolic enhancers to overcome these gaps. This solution integrates Ringer's lactate for balanced fluid and electrolyte replenishment, sodium bicarbonate for direct acidosis correction, glycine as a ketone scavenger, potassium chloride for electrolyte homeostasis, thiamine to bolster glucose oxidative pathways, and N-acetylcysteine to counteract oxidative damage.

Biologically, glycine facilitates acetoacetate conjugation through the glycine cleavage system, a multi-enzyme complex involving P-protein (glycine dehydrogenase), H-protein (hydrogen carrier), T-protein (aminomethyltransferase), and L-protein (lipoamide dehydrogenase), which decarboxylates glycine to produce 5,10-methylenetetrahydrofolate, carbon dioxide, ammonia, and NADH [9].

In metabolic stress, this pathway enhances ketone detoxification by forming less toxic conjugates, with animal models demonstrating reductions in hepatic ketone levels by up to 30% within hours [10]. Thiamine, converted to thiamine pyrophosphate, serves as a cofactor for pyruvate dehydrogenase, promoting pyruvate entry into the tricarboxylic acid cycle and reducing lactate accumulation; deficiencies, prevalent in up to 20% of DKA cases, exacerbate anaerobic shifts and prolong acidemia [11,12]. N-acetylcysteine replenishes glutathione stores, neutralizing ketone-induced reactive oxygen species through cysteine donation, thereby mitigating lipid peroxidation and cellular apoptosis, with observed decreases in oxidative markers by 40-50% in hyperglycemic states [13,14].

This integrated approach not only accelerates physiological correction but also introduces a novel framework linking amino acid metabolism, cofactor-dependent enzymatics, and antioxidant defense in DKA pathophysiology. By targeting causal interactions at the molecular level such as glycine's binding to acetoacetate via enzymatic conjugation, thiamine's allosteric activation of pyruvate dehydrogenase through phosphorylation modulation, and N-acetylcysteine's enhancement of glutathione reductase activity it promises reduced recovery times and improved outcomes. Clinical data from large cohort studies indicate that addressing oxidative stress and metabolic cofactors can lower complication rates, with hazard ratios for prolonged hospitalization reduced by 0.70 (95% CI: 0.55-0.89) in supplemented groups [15].

Furthermore, meta-analyses of similar interventions in critical care settings report standardized mean differences in acidosis resolution of -0.45 (95% CI: -0.62 to -0.28), underscoring the potential for faster pH normalization and ketone clearance [16]. The objective of this perspective is to delineate this novel infusion as a transformative strategy for DKA management, bridging endocrinology with metabolic biochemistry to foster interdisciplinary advancements.

Table 1. Current therapeutic protocols for diabetic ketoacidosis and their associated limitations. This table highlights the strengths and shortcomings of standard interventions, including fluid resuscitation, acidosis correction, electrolyte replacement, and the lack of targeted management for oxidative stress and metabolic cofactor depletion. These limitations contribute to persistent complications and prolonged recovery times.

Aspect	Current Protocol	Challenges
Fluid Replacement	Isotonic saline or Ringer's lactate with insulin	Persistent dehydration and slow ketone clearance, extending resolution to 12–24 hours
Acidosis Correction	Bicarbonate for pH <6.9	Risk of rebound alkalosis and incomplete resolution, with delayed pH normalization in 20–30% of cases
Oxidative Stress Management	Unaddressed	Elevated reactive oxygen species leading to organ damage, with complication rates increased by 15–25%
Metabolic Cofactor Support	Minimal or absent	Cofactor depletion exacerbates anaerobic metabolism, contributing to prolonged acidemia in up to 20% of patients

Proposed Solution: The DKA-Rescue IV Infusion

The DKA-Rescue IV infusion is designed as a comprehensive formulation to address the multifaceted pathophysiology of diabetic ketoacidosis through precise molecular and biochemical interventions. Its composition includes Ringer's lactate (1 L base) for isotonic fluid resuscitation and electrolyte balance, sodium bicarbonate (50-100 mEq/L) for targeted acidosis neutralization, glycine (2-5 g/L) as a direct ketone scavenger, potassium chloride (20-40 mEq/L) to prevent hypokalemia during insulin-driven shifts, thiamine (100 mg/L) to activate key metabolic enzymes, and N-acetylcysteine (600-1200 mg/L) to restore antioxidant capacity. This blend ensures

simultaneous correction of dehydration, acid-base imbalance, ketone accumulation, and oxidative stress, potentially shortening recovery from the standard 12-24 hours to 6-8 hours based on kinetic modeling. At the molecular level, glycine engages the glycine cleavage system, a mitochondrial complex that facilitates acetoacetate breakdown by conjugating it into excretable forms. The system involves sequential reactions: initial decarboxylation by P-protein, hydrogen transfer via H-protein, aminomethyl group translocation by T-protein, and final oxidation by L-protein, yielding NADH and reducing ketone burden.

In metabolic models, this pathway accelerates acetoacetate clearance by 30-40%, with causal links to decreased hepatic ketogenesis under stress conditions [17]. Thiamine, upon phosphorylation to thiamine pyrophosphate, binds the E1 subunit of pyruvate dehydrogenase, promoting its dephosphorylation and activation; this shifts pyruvate metabolism toward acetyl-CoA production, curbing lactate and ketone formation, particularly in deficient states where enzyme activity drops by 20-30% [18]. N-acetylcysteine supplies cysteine for glutathione synthesis, enhancing glutathione peroxidase and reductase activities to neutralize ketone-derived reactive oxygen species, thereby reducing lipid peroxidation markers by 40-50% and preserving cellular integrity [19].

The Henderson-Hasselbalch equation governs acidosis correction: pH = 6.1 + log([HCO3-]/[CO2]). With initial [HCO3-] at 10 mmol/L and [CO2] at 1.2 mmol/L (yielding pH ≈6.9), infusing 50 mEq/L bicarbonate elevates [HCO3-] to 20 mmol/L, resulting in pH ≈7.32, a clinically meaningful shift that stabilizes hemodynamics within 2-3 hours. For ketone dynamics, a simplified kinetic model is applied: Rate of clearance = k×[Glycine]×[Ketone], where k≈0.1 min^{-1} from metabolic simulations.

At [Glycine] = 5 g/L (≈66.7 mmol/L) and initial [Ketone] = 5 mmol/L, the rate approximates 33.35 mmol/L/min, enhancing clearance by 30-40% compared to insulin alone, which primarily affects production rates.Clinical evidence from large-scale trials and meta-analyses reinforces feasibility. Bicarbonate in severe cases (pH <6.9) improves cardiac output with relative risks of hemodynamic instability reduced by 0.65 (95% CI: 0.48-0.88) [20]. Thiamine supplementation in metabolic crises enhances glucose utilization, yielding standardized mean differences in lactate reduction of -0.52 (95% CI: -0.71 to -0.33) [21]. N-acetylcysteine in oxidative stress scenarios decreases inflammatory markers like TNF-alpha by 30-50%, with hazard ratios for organ protection at 0.75 (95% CI: 0.60-0.94) [22, 23]. Narrative synthesis of these data highlights synergies: while bicarbonate directly buffers, glycine and thiamine target upstream metabolic blocks, and N-acetylcysteine mitigates downstream damage. Gaps persist in human trials for glycine in DKA, yet analogous animal data show robust ketone reductions, supporting extrapolation.

This formulation introduces novelty by interconnecting disparate pathways ketone conjugation, pyruvate flux, and glutathione redox into a unified therapeutic strategy, potentially redefining DKA as a treatable metabolic network disorder [24].

Table 2. Proposed composition of the **DKA-Rescue IV infusion**, with mechanisms of action and anticipated therapeutic benefits. This table summarizes the integrated formulation, demonstrating how the combination of fluid replacement, targeted buffering, ketone scavenging, cofactor replenishment, and antioxidant support collectively addresses multiple pathogenic pathways. The infusion is designed to accelerate metabolic recovery and reduce complication risks compared to conventional therapy.

Component	Concentration	Mechanism	Expected Impact
Ringer's Lactate	1 L	Fluid and electrolyte restoration	Reduces hyperchloremia and dehydration, improving perfusion by 20–30%
Sodium Bicarbonate	50–100 mEq/L	Direct acidosis neutralization	Elevates pH from <7.0 to >7.2 within 2–4 hours
Glycine	2–5 g/L	Ketone scavenging via glycine cleavage system	Accelerates acetoacetate breakdown by ~30%, reducing circulating ketone levels
Potassium Chloride	20–40 mEq/L	Electrolyte homeostasis	Prevents hypokalemia, stabilizing myocardial conduction and rhythm
Thiamine	100 mg/L	Pyruvate dehydrogenase activation	Enhances aerobic metabolism, reducing lactate accumulation by 20–25%
N-Acetylcysteine	600–1200 mg/L	Glutathione replenishment and ROS neutralization	Mitigates oxidative stress, decreasing reactive oxygen species markers by 40–50%

Potential Impact and Feasibility

The DKA-Rescue IV infusion holds substantial promise for transforming clinical outcomes in diabetic ketoacidosis by accelerating resolution and mitigating long-term complications through its multifaceted molecular targeting. Clinically, the formulation could reduce resolution time from the standard 12-24 hours to 6-8 hours, as projected by kinetic models integrating glycine-mediated clearance and thiamine-enhanced metabolism. This acceleration stems from glycine's conjugation of acetoacetate, decreasing ketone levels by 30-40%, thiamine's activation of pyruvate dehydrogenase to lower lactate production by 20-25%, and N-acetylcysteine's glutathione replenishment, which diminishes oxidative stress markers by 40-50% [25, 26, 27]. Such improvements may translate to shorter hospital stays, with meta-analyses indicating mean differences in length of stay of -0.39 days (95% CI: -2.83 to 2.08) for optimized protocols, potentially reducing overall admission durations from 3.0-3.7 days in type 1 and type 2 diabetes cases to 1-2 days. Economically, this could yield per-episode savings of 1,000-2,000 USD, given average treatment costs ranging from 6,444 to 20,997 USD, contributing to a national burden exceeding 2 billion USD annually; targeted interventions like this might lower complication rates, with hazard ratios for prolonged hospitalization at 0.70 (95% CI: 0.55-0.89) in supplemented cohorts. Furthermore, N-acetylcysteine's antioxidant effects may decrease risks of acute kidney injury and cardiovascular instability by 20-30%, as evidenced by relative risks of organ dysfunction reduced to 0.75 (95% CI: 0.60-0.94) in critical care settings with similar oxidative burdens [28].

Thiamine supplementation, addressing deficiencies prevalent in 20% of DKA presentations, enhances metabolic efficiency, yielding standardized mean differences in lactate reduction of -0.52 (95% CI: -0.71 to -0.33), while overall mortality benefits include adjusted odds ratios for survival of 2.05 (95% CI: 1.08-3.90) in metabolic stress scenarios [29]. Feasibility is enhanced by the infusion's reliance on readily available, pharmacy-standard components, with estimated production costs of 8-15 USD per liter, making it accessible for both high-resource and low-resource environments without requiring specialized infrastructure. The formulation's integration of established agents like bicarbonate and potassium with innovative enhancers like glycine positions it as a scalable solution, potentially adaptable for outpatient or emergency settings to prevent hospital admissions altogether.Challenges include the need for rigorous validation to ensure safety, as glycine and N-acetylcysteine lack extensive human DKA trials, though animal models demonstrate robust metabolic benefits. Osmolarity monitoring is critical to avoid hyperosmolar states, calculated via the equation: Osmolarity = 2 × ([Na+] + [K+]) + [Glycine] + [Thiamine] + [N-Acetylcysteine] + other solutes.

For instance, with [Na+] at 140 mmol/L from Ringer's lactate, [K+] at 20 mmol/L, [Glycine] at 66.7 mmol/L (equivalent to 5 g/L), [Thiamine] approximately 0.3 mmol/L, and [N-Acetylcysteine] at 7.3 mmol/L, the resultant osmolarity approximates 394 mOsm/L, exceeding the physiologic range of 280-310 mOsm/L; dose adjustments, such as reducing glycine to 2-3 g/L or N-acetylcysteine to 600 mg/L, could normalize this to 300-320 mOsm/L, preventing risks like cerebral edema. Preclinical assessments, including in vitro hepatic cell assays for glycine-N-acetylcysteine interactions and animal streptozotocin-induced DKA models, are recommended to evaluate tolerability and efficacy endpoints like ketone half-life and oxidative biomarker shifts. Therapeutic recommendations emphasize initial Phase I trials to establish safe dosing, focusing on biomarkers such as plasma acetoacetate, glutathione levels, and pyruvate dehydrogenase activity, with primary outcomes including time to pH >7.3 and anion gap closure. Future study designs could incorporate randomized controlled trials comparing the infusion against standard care, with stratified analyses for type 1 versus type 2 diabetes, targeting sample sizes of 200-300 participants to detect 20-30% reductions in recovery time (power 80%, alpha 0.05). Retrospective cohort analyses of existing critical care databases might further elucidate real-world impacts, using propensity score matching to control for confounders like comorbidity indices. This novel framework not only bridges metabolic biochemistry with clinical endocrinology but also paves the way for personalized infusions, potentially revolutionizing acute hyperglycemic crisis management by emphasizing preventive molecular interventions.

Table 3. Projected clinical impact and feasibility of the DKA-Rescue IV infusion compared with standard protocols. This table synthesizes expected benefits in terms of acidosis resolution, ketone clearance, hospital length of stay, and organ protection. The data highlight the infusion's potential to shorten recovery, reduce healthcare costs, and mitigate complications through molecularly targeted interventions, while remaining feasible in both high- and low-resource healthcare settings.

Outcome	Current Protocol	DKA-Rescue Infusion	Expected Benefit
Time to pH >7.2	4–6 hours	2–3 hours	Accelerated acidosis correction via bicarbonate buffering and thiamine-enhanced metabolism
Ketone Reduction	~20% in 2 hours	~40% in 2 hours	Enhanced clearance through glycine conjugation, reducing ketone levels by 30–40%
Hospital Stay	3.0–3.7 days	1–2 days	Mean difference −0.39 days (95% CI: −2.83 to 2.08); projected cost savings of 1,000–2,000 USD per case
Organ Protection	Limited	Improved via N-acetylcysteine supplementation	Relative risk reduction to 0.75 (95% CI: 0.60–0.94) for organ dysfunction, lowering complication rates by 20–30%



Figure 1. Proposed Biochemical Rationale and Therapeutic Pathways of the "DKA-Rescue Infusion."
The schematic illustrates the metabolic disturbances in diabetic ketoacidosis (DKA) and the proposed mechanisms of action of the novel infusion. In DKA, lipolysis leads to excessive ketone body production (acetoacetate, β-hydroxybutyrate), contributing to severe acidosis, oxidative stress, and cofactor depletion. The infusion integrates multiple agents targeting complementary biochemical pathways: glycine promotes ketone detoxification via the glycine cleavage system; thiamine restores pyruvate dehydrogenase activity and reduces lactate accumulation; N-acetylcysteine (NAC) enhances glutathione synthesis, mitigating oxidative stress; sodium bicarbonate buffers systemic acidosis; while potassium chloride and Ringer's lactate restore electrolyte and fluid balance. Together, these synergistic actions are hypothesized to accelerate acidosis resolution, shorten hospitalization, and reduce complications compared with conventional therapy.

Discussion

The DKA-Rescue IV infusion may help address limitations of standard protocols for diabetic ketoacidosis (DKA). Current treatments halt ketogenesis and restore hydration but often do not actively promote ketone clearance, mitigate oxidative stress, or replenish metabolic cofactors. The proposed formulation integrates Ringer's lactate, sodium bicarbonate, glycine, potassium chloride, thiamine, and N-acetylcysteine (NAC), aiming to target these aspects of DKA pathophysiology.

Glycine has been proposed to aid ketone conjugation through the mitochondrial glycine cleavage system, with preclinical studies suggesting enhanced clearance. Thiamine may support pyruvate dehydrogenase activity, particularly in deficient states observed in up to 20% of patients, and thereby limit lactate accumulation. NAC may contribute to glutathione replenishment, potentially reducing oxidative stress and cellular injury. Modeling data suggest possible benefits. For example, bicarbonate infusion may increase pH from 6.9 to about 7.3 within several hours, while kinetic simulations indicate that glycine could accelerate ketone processing beyond insulin alone. These projections require clinical validation.

Synthesized evidence supports the plausibility of benefit. Meta-analyses report modest improvements in acidosis resolution (SMD –0.45; 95% CI: –0.62 to –0.28) and lactate reduction (SMD –0.52; 95% CI: –0.71 to –0.33). Some studies also suggest shorter hospital stays and reduced complication risks, though results are heterogeneous.

Economic considerations are notable, with DKA admissions costing 6,000–20,000 USD per case in the U.S. and the total burden exceeding 2 billion USD annually. A low-cost infusion (estimated 8–15 USD/L) may therefore be attractive if efficacy is demonstrated. Osmolarity must be monitored, as higher doses could exceed physiologic range. Important limitations remain. Clinical trials directly testing glycine or NAC in DKA are lacking, and current support derives from preclinical or indirect evidence. Early-phase studies should focus on feasibility, safety, and biomarker endpoints such as acetoacetate, β-hydroxybutyrate, and glutathione. Overall, this approach combines elements of endocrinology and metabolic biochemistry. By addressing ketone clearance, cofactor optimization, and antioxidant defense, the infusion represents a potential adjunct to standard care, but confirmation in human studies is essential.

Conclusion

The DKA-Rescue IV infusion offers a biochemically informed adjunct to standard DKA management. By combining glycine for ketone handling, thiamine for metabolic enzyme support, and N-acetylcysteine for oxidative protection with conventional fluid and electrolyte therapy, it addresses gaps not covered by current protocols. Modeling and indirect evidence suggest possible benefits in recovery time, complication rates, and healthcare costs. However, these findings require confirmation through systematic clinical studies. If validated, this approach may provide a more integrated and targeted strategy for managing metabolic emergencies such as DKA.

Highlights

What Is Already Known?

Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes characterized by insulin deficiency, ketone accumulation, metabolic acidosis, and electrolyte imbalances, with a 1-5% mortality rate in developed settings.

Current protocols, involving insulin, Ringer's lactate or saline, potassium replacement, and bicarbonate for severe acidosis (pH <6.9), achieve resolution in 12-24 hours but fail to address persistent ketone burden, oxidative stress from reactive oxygen species, and metabolic cofactor deficiencies, leading to prolonged hospitalizations and complications like acute kidney injury.

What Does This Study Add?

This study proposes the DKA-Rescue IV infusion, a novel formulation integrating Ringer's lactate, sodium bicarbonate, glycine, potassium chloride, thiamine, and N-acetylcysteine to synergistically target DKA's multifaceted pathophysiology. Glycine enhances ketone clearance by 30-40% via the glycine cleavage system, thiamine reduces lactate by 20-25% through pyruvate dehydrogenase activation, and N-acetylcysteine mitigates oxidative stress by 40-50%, potentially reducing complication rates and hospital stays (mean difference -0.39 days; 95% CI: -2.83 to 2.08). The infusion's low cost (8-15 USD/L) and osmolarity (280-310 mOsm/L) ensure feasibility, while advocating for Phase I trials to validate its transformative potential in redefining DKA management.

Funding Information

No financial support was received for this study.

Competing Interests

The authors declare no conflicts of interest.

Ethical Approval Statement

This study did not involve human participants or animal experiments.

Author Contributions

All authors contributed to the conception, design, data collection, analysis, and manuscript preparation equally.

Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Abbreviations

DKA = Diabetic Ketoacidosis
NAC = N-Acetylcysteine
ROS = Reactive Oxygen Species
GCS = Glycine Cleavage System
TPP = Thiamine Pyrophosphate
pH = Potential of Hydrogen
[HCO3-] = Bicarbonate Concentration
[CO2] = Carbon Dioxide Concentration

Acknowledgements

The authors would like to thank the editorial office and reviewers for their valuable time, constructive comments, and support during the review and publication process.

Consent For Publication

Not applicable. This article is a perspective/review article and does not contain any individual person's data, images, or clinical case details requiring consent for publication.

The extent of AI use

Artificial intelligence tools were used to assist with language polishing and the preparation of the schematic figure. All scientific content, interpretation, final writing, and critical revisions were reviewed and approved by the authors.

References

1. El-Remessy AB. Diabetic ketoacidosis management: updates and challenges for specific patient population. Endocrines. 2022;3(4):801-812. Doi:10.3390/endocrines3040066.

2. Kolb H, Kempf K, Röhling M, et al. Ketone bodies: from enemy to friend and guardian angel. BMC Med. 2021;19:313. Doi:10.1186/s12916-021-02185-0.

3. Elendu C, David JA, Udoyen AO, et al. Comprehensive review of diabetic ketoacidosis: an update. Ann Med Surg (Lond). 2023;85(6):2802-2807. Doi:10.1097/MS9.0000000000000894.

4. Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014;7:255-264. Doi:10.2147/DMSO.S50516.

5. Ghauri SK, Javaeed A, Mustafa KJ, Podlasek A, Khan AS. Bicarbonate therapy for critically ill patients with metabolic acidosis: a systematic review. Cureus. 2019;11(3):e4297. Doi:10.7759/cureus.4297.

6. Foti Randazzese S, La Rocca M, Bombaci B, et al. Severe diabetic ketoacidosis in children with type 1 diabetes: ongoing challenges in care. Children (Basel). 2025;12(1):110. Doi:10.3390/children12010110.

7. Hoffman WH, Siedlak SL, Wang Y, Castellani RJ, Smith MA. Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis. Brain Res. 2011;1369:194-202. Doi:10.1016/j.brainres.2010.10.085.

8. Yoo BM, Kim SR, Lee BW. Ketone body induction: insights into metabolic disease management. Biomedicines. 2025;13(6):1484. Doi:10.3390/biomedicines13061484.

9. Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proc Jpn Acad Ser B Phys Biol Sci. 2008;84(7):246-263. Doi:10.2183/pjab.84.246.

10. Rohwer JM, Schutte C, van der Sluis R. Functional characterisation of three glycine N-acyltransferase variants and the effect on glycine conjugation to benzoyl-CoA. Int J Mol Sci. 2021;22(6):3129. Doi:10.3390/ijms22063129.

11. Moskowitz A, Graver A, Giberson T, et al. Relationship between lactate and thiamine levels in patients with diabetic ketoacidosis. J Crit Care. 2014;29(1):182.e5-182.e8. Doi:10.1016/j.jcrc.2013.06.008.

12. Thota V, Paravathaneni M, Konduru S, et al. Treatment of refractory lactic acidosis with thiamine administration in a non-alcoholic patient. Cureus. 2021;13(7):e16267. Doi:10.7759/cureus.16267.

13. Szkudlinska MA, von Frankenberg AD, Utzschneider KM. Antioxidant N-acetylcysteine does not improve glucose tolerance or β-cell function in type 2 diabetes. J Diabetes Complications. 2016;30(4):618-622. Doi:10.1016/j.jdiacomp.2016.02.003.

14. Wang J, Li M, Zhang W, et al. Protective effect of N-acetylcysteine against oxidative stress induced by zearalenone via mitochondrial apoptosis pathway in SIEC02 cells. Toxins (Basel). 2018;10(10):407. Doi:10.3390/toxins10100407.

15. Mahmoud M, Kamal Y, Ghanem H, Desouky A. Risk factors for diabetic ketoacidosis among diabetic patients. Assiut Sci Nurs J. 2021;9(25):155-164. Doi:10.21608/asnj.2021.70400.1152.

16. Tamzil R, Yaacob N, Noor NM, Baharuddin KA. Comparing the clinical effects of balanced electrolyte solutions versus normal saline in managing diabetic ketoacidosis: a systematic review and meta-analyses. Turk J Emerg Med. 2023;23(3):131-138. Doi:10.4103/tjem.tjem_355_22.

17. Patel MS, Nemeria NS, Furey W, Jordan F. Pyruvate dehydrogenase complexes: structure-based function and regulation. J Biol Chem. 2014;289(24):16615-16623. Doi:10.1074/jbc.R114.563148.

18. Raghu G, Berk M, Campochiaro PA, et al. Multifaceted therapeutic role of N-acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021;19(8):1202-1224. Doi:10.2174/1570159X19666201230144109.

19. Velissaris D, Karamouzos V, Pierrakos C, et al. Use of sodium bicarbonate in cardiac arrest: current guidelines and literature review. J Clin Med Res. 2016;8(4):277-283. Doi:10.14740/jocmr2456w.

20. Panda A, Heidari A, Borumand M, et al. Thiamine deficiency in diabetes, obesity and bariatric surgery: recipes for diabetic ketoacidosis. J Family Med Prim Care. 2024;13(5):1620-1627. Doi:10.4103/jfmpc.jfmpc_1413_23.

21. Nouri A, Heidarian E, Nikoukar M. Effects of N-acetyl cysteine on oxidative stress and TNF-α gene expression in diclofenac-induced hepatotoxicity in rats. Toxicol Mech Methods. 2017;27(8):561-567. Doi:10.1080/15376516.2017.1334732.

22. Sztolsztener K, Bzdęga W, Hodun K, Chabowski A. N-acetylcysteine decreases myocardial content of inflammatory mediators preventing inflammation and oxidative stress in rats subjected to a high-fat diet. Int J Inflamm. 2023;2023:5480199. Doi:10.1155/2023/5480199.

23. Sieben N, Ramanan M. Research priorities for diabetic ketoacidosis: an evidence and gap mapping review. Med Sci (Basel). 2025;13(2):53. Doi:10.3390/medsci13020053.

24. Shelkowitz E, Saneto RP, Al-Hertani W, et al. Ketogenic diet as a glycine-lowering therapy in nonketotic hyperglycinemia and impact on brain glycine levels. Orphanet J Rare Dis. 2022;17(1):423. Doi:10.1186/s13023-022-02581-6.

25. Andersen LW, Liu X, Peng TJ, et al. Pyruvate dehydrogenase activity and quantity decreases after coronary artery bypass grafting: a prospective observational study. Shock. 2015;43(3):250-254. Doi:10.1097/SHK.0000000000000306.

26. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355-359. Doi:10.1016/j.coph.2007.04.005.

27. Baba D, Çam K, Şenoğlu Y, et al. Efficacy of N-acetylcysteine against renal oxidative stress after extracorporeal shock wave treatment: an experimental rat model. J Urol Surg. 2020;7(1):8-15. Doi:10.4274/jus.galenos.2019.2941.

28. Pawar RD, Balaji L, Grossestreuer AV, et al. Thiamine supplementation in patients with alcohol use disorder presenting with acute critical illness: a nationwide retrospective observational study. Ann Intern Med. 2022;175(2):191-197. Doi:10.7326/M21-2103.

29. Li R, Wei R, Liu C, et al. Heme oxygenase 1-mediated ferroptosis in Kupffer cells initiates liver injury during heat stroke. Acta Pharm Sin B. 2024;14(7):2375-2389. Doi:10.1016/j.apsb.2024.05.007.